期刊文献+

溶血磷脂酸在卵巢癌进展中的机制研究 被引量:5

Mechanisms of Lysophosphatidic Acid Involved in the Progression of Ovarian Cancer
下载PDF
导出
摘要 在卵巢癌的发生发展中,脂代谢发挥重要作用,溶血磷脂酸(LPA)作为一种生物活性磷脂分子,通过与多种G蛋白偶联受体结合,参与卵巢癌的增殖、转移和侵袭活动。一方面,LPA可通过促进肿瘤血管新生、调节细胞周期、抑制凋亡、促进糖代谢及维持肿瘤干细胞(CSC)的特性来促进卵巢癌细胞增殖;另一方面,LPA可增加基质金属蛋白酶(MMP)及尿激酶型纤溶酶原激活物(u PA)的表达、干预细胞间连接和骨架蛋白、促进上皮-间质转化(EMT),进而促进卵巢癌的转移和侵袭。此外,卵巢癌患者血浆中高水平的LPA单独或与卵巢癌的其他肿瘤标记物联合检测具有更高的敏感度和特异度。综述LPA在卵巢癌增殖、转移和侵袭中的作用机制以及潜在的诊断、治疗靶点方面的研究进展。 In the development of ovarian cancer,the aberrant lipid metabolism plays a critical role.Lysophosphatidic acid(LPA),a bioactive molecular,can bind to different G protein-coupled receptors and stimulate the proliferation,metastasis and invasion of ovarian cancer.On one hand,LPA could stimulate proliferation by promoting angiogenesis,regulating cell cycle,inhibiting apoptosis,promoting glucose metabolism and maintaining cancer stem cell(CSC) characteristics.On the other hand,LPA could stimulate the metastasis and invasion by enhancing the expression of matrix metalloproteinases(MMPs) and urokinase-type plasminogen activator(u PA),interfering intercellular junctions and cytoskeletons and inducing epithelial-mesenchymal transition(EMT).Besides,testing plasma level of LPA alone or combining with other tumor biomarkers is more sensitive and specific.In this article,we review the latest knowledge on the molecular mechanism of LPA in the proliferation,migration and invasion of ovarian cancer as well as potential biological targets.
作者 郑亚 孙红
出处 《国际妇产科学杂志》 CAS 2016年第6期673-676,共4页 Journal of International Obstetrics and Gynecology
基金 上海市科学技术委员会科研计划(14ZR1404100)
关键词 卵巢肿瘤 溶血磷脂酸 信号通路 治疗靶点 诊断 Ovarian neoplasms Lysophosphatidic acid Signal path Therapeutic targets Diagnosis
  • 相关文献

参考文献2

二级参考文献22

  • 1SedlOkovO I, VtvrovO J, Toner J, et al. Lysophosphatidic acid (LPA) :a perspective marker in ovarian cancer[ J]. Tumour Biol, 2011, 32(2) :311-316.
  • 2Cherfils J, Zeghouf M. Regulation of small GTPases by GEFs, GAPs, and GDIs[J]. Phvsiol Rev. 2013, 93 ( 1 ) :269-309.
  • 3Choi JW, Herr DR, Noguchi K, et al. LPA receptors : subtypesand biological actions [J]. Annu Rev Pharmacol Toxicol, 2010, 50:157-186.
  • 4Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers [ J ]. JAMA, 1998, 280(8):719-723.
  • 5Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients[ J]. Clin Cancer Res, 1995, 1 (10) : 1223-1232.
  • 6Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells[ J]. J Natl Cancer Inst, 2001, 93 (10) :762-768.
  • 7Yang D, Yang W, Zhang Q, et al. Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2[J]. Oneol Lett, 2013, 5(3):1048-1052.
  • 8Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion [ J ]. Cancer Metastasis Rev, 2009, 28 (1-2) : 15-33.
  • 9Lee TK, Poon RT, Yuen AP, et al. Rac activation is associated with hepatocellular carcinoma metastasis by up-regulation of vascular endothelial growth factor expression [ J ]. Clin Cancer Res, 2006, 12(17) :5082-5089.
  • 10Lanrin M, Huber J, Penetier A, et al. Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis[ J]. Proc Natl Acad Sci U S A, 2013, 110 (18) :7434-7439.

共引文献17

同被引文献62

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部